UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In 2005, The University of Alabama at Birmingham established a NIDDK-funded, interdisciplinary center of excellence in PKD-related research, with specific emphasis on recessive PKD. In the previous Core Center award period, we developed a Core Resource to capture clinical and mutational data for ARPKD patients ("Core A: ARPKD Clinical and Genetic Resource", NCT00575705). However, studies in the last several years have demonstrated that ARPKD and other single gene disorders characterized by renal cystic disease and extra-renal phenotypes share numerous pathogenic features. In the current competitively- renewed Center, we have expanded this Core resource to include other hepato/renal fibrocystic diseases.
Goals for the Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource are:
- Clinical Database:
• Expand our comprehensive Clinical Database to include information from all patients who meet the inclusion criteria for hepato/renal fibrocystic diseases.
- Mutational Database:
Test children with ARPKD and other hepato/renal fibrocystic disease to identify genetic mutations, establish a DNA bank for patients with hepato/renal fibrocystic diseases and develop a Mutational Database. This Database will be capable of linking clinical and mutational information via a unique identifier in a searchable format to facilitate genetic research (e.g. genotype-phenotype correlations, new disease gene studies, and modifier gene studies), translational studies, and clinical trials.
3- Tissue Resource:
Much of the research that is performed on diseases of the kidney, including recessive genetic diseases, requires human tissue from both affected as well as non-affected (controls) individuals. In this Core Resource, we are establishing an independent tissue resource which would supply investigators throughout North America with samples of hepato/renal fibrocystic disease affected tissues for studies of these disorders.
4- Educational Resource:
- Expand our multi-media, web-based resource to provide a reliable up-to-date, and comprehensive informational resource for ARPKD and Hepato/Renal Diseases families, their physicians, and genetic counselors.
All the information regarding participation in "Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource" is available at: http://www.arpkdstudies.uab.edu/.
| Condition |
|---|
|
Hepato/Renal Fibrocystic Disease Autosomal Recessive Polycystic Kidney Disease Joubert Syndrome Bardet Biedl Syndrome Meckel-Gruber Syndrome Congenital Hepatic Fibrosis Caroli Syndrome Oro-Facial-Digital Syndrome Type I Nephronophthisis Glomerulocystic Kidney Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource (Hepato/Renal Fibrocystic Diseases Core Center (UAB HFRDCC)) |
Blood-derived DNA and lymphocytes for EBV-immortalized cell lines. Remnant tissue samples affected with Hepato/Renal Fibrocystic Diseases
| Estimated Enrollment: | 200 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | September 2015 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | up to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
In view of the genetics and demographics of the recessive disorders comprising the spectrum of hepato/renal fibrocystic diseases, we estimate that 50% of the subjects will be female; that 90% of the subjects will be Caucasian and the remainder will belong to the following racial/ethnic categories: 5% African-Americans; 3% Hispanics; 1% Asians; and 1% or less will be other categories.
Inclusion Criteria:
- Demonstration of hepato/renal fibrocystic disease by clinical information, imaging studies, biopsy, autopsy, or genetic testing.
Exclusion Criteria:
- ADPKD Urinary tract malformations Major congenital anomalies of other systems
Contacts and Locations| United States, Alabama | |
| University of Alabama at Birmingham | Recruiting |
| Birmingham, Alabama, United States, 35294 | |
| Contact: Teresa J. Chacana, BSN 205-934-7649 tchacana@uab.edu | |
| Contact: Lisa M. Guay-Woodford, MD 202-476-6439 lguaywoo@cnmc.org | |
| Principal Investigator: Lisa M. Guay-Woodford, MD | |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr. Lisa Guay-Woodford, Principal Investigator, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT01401998 History of Changes |
| Other Study ID Numbers: | F110414002, 2P30DK074038-06 |
| Study First Received: | July 22, 2011 |
| Last Updated: | June 22, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of Alabama at Birmingham:
|
cystic kidney disease polycystic kidney disease congenital hepatic fibrosis genetic disease |
Additional relevant MeSH terms:
|
Orofaciodigital Syndromes Bardet-Biedl Syndrome Laurence-Moon Syndrome Cysts Liver Diseases Cystic Fibrosis Fibrocystic Breast Disease Fibrosis Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Recessive Caroli Disease Liver Cirrhosis Ciliary Motility Disorders Encephalocele |
Cerebellar Diseases Eye Abnormalities Kidney Diseases, Cystic Neoplasms Pathological Conditions, Anatomical Digestive System Diseases Pancreatic Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Breast Diseases Skin Diseases Pathologic Processes Urologic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013